Definium Therapeutics
DFTX
88 hedge funds and large institutions have $12.6M invested in Definium Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 19 closing their positions.
879% more call options, than puts
Call options by funds: $9.78M | Put options by funds: $999K
13% more capital invested
Capital invested by funds: $11.1M → $12.6M (+$1.41M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.12% less ownership
Funds ownership: 13.48% → 10.36% (-3.1%)
15% less funds holding
Funds holding: 104 → 88 (-16)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$447K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$220K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$194K |
| 4 |
Renaissance Technologies
New York
|
+$185K |
| 5 |
State Street
Boston,
Massachusetts
|
+$76.8K |
Top Sellers
| 1 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$1.19M |
| 2 |
Millennium Management
New York
|
-$549K |
| 3 |
Goldman Sachs
New York
|
-$236K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$205K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$191K |
DFTX Hedge Fund Activity: Q1 2023 in Review
88 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2023, worth a combined $12.6M — up 13% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of DFTX and 8 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was Two Sigma Investments, adding an estimated $447K. The largest seller was Merit Financial Group, exiting entirely with an estimated $1.19M sold.
- 88 institutional investors held Definium Therapeutics (DFTX) as of Q1 2023, down from 104 in Q4 2022.
- Funds reported $12.6M of Definium Therapeutics stock for Q1 2023, up 13% quarter-over-quarter.
- 8 funds opened new Definium Therapeutics positions in Q1 2023 and 19 closed out, a net change of -11 holders.
- The largest Definium Therapeutics buyer in Q1 2023 was Two Sigma Investments, an estimated $447K added.
- The largest Definium Therapeutics seller in Q1 2023 was Merit Financial Group, an estimated $1.19M sold.
Based on aggregated 13F filings for Q1 2023.